AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy has been approved in the U.S. for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. The approved regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Novo Nordisk’s Ozempic and Wegovy Prices Cut 71% under Medicare Plan
- FDA approves AstraZeneca’s Imfinzi as perioperative immunotherapy for GEJ cancer
- AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation
- Harbour BioMed advances collaboration with AstraZeneca
- AstraZeneca plans $2B manufacturing investment in Maryland